Effects of conjugated linoleic acid on serum Apo B and MDA in type II diabetic patients

ABSTRACT

Some animal studies have suggested that Conjugated Linoleic acid [CLA] supplementation may have therapeutic potential with respect to lipid metabolism, considered to be the most important cardiovascular disease [CVD] related risk factor, associated with type 2 diabetes mellitus [T2DM]. However, results from human studies on risk markers of diabetes are ambiguous. This study was carried out to determine the effect of CLA supplementation [as 5050 proportions of c9, t11 and t10, c12 CLA isomers] on serum lipid profiles, MDA, apo-B100, systolic and diastolic blood pressures in patients with T2DM. The study was a randomized double-blind, placebo-controlled parallel intervention. Participants were 39 T2DM patients [35 to 50 y, 30>BMI >25] stratified, according to sex, age and BMI into two groups. The intervention group took 3.0 g CLA/d [3x1 g, capsules], a 5050 isomer blend of c9, t11 and t10, c12 CLA] while the control group took soy bean oil as CLA placebo for 8 weeks. Blood pressure, serum lipid profile, MDA, and Apo B were measured at baseline and at the end of the intervention. There were no significant differences in serum triacylglycerol, total cholesterol, LDL-C, HDL-C, apo-B100 and MDA between the two groups after week 8; nor were any significant differences observed in systolic and diastolic blood pressure between the two groups after intervention. Results of this study suggest that short term CLA supplementation [3g/d] may not improve lipid profiles, apo-B100 and MDA concentrations in T2DM patients